FDA denies approval of generic Lovenox

Novartis AG and biotechnology firm Momenta Pharmaceuticals' generic version of anti-clotting drug Lovenox has been rejected by the FDA due to concerns about the treatment's effect on the immune system. Momenta executives said they would work with the FDA to address their concerns.

View Full Article in:

Boston Globe (tiered subscription model), The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD